Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most high-level use, fixed combination, and key safety concepts (CHF/fluid retention and metformin-associated lactic acidosis context) are broadly consistent with provided excerpts. However, several claims are not supported by the supplied label text (e.g., pregnancy/breastfeeding phrasing, precise mechanism statements for metformin, generalization of GI frequency by metformin, and details on dosing adjustment/tolerability). Missing material labeling content includes contraindications (NYHA III/IV) and lactic acidosis precautions/management specifics.
Category Scores
Accurate Statements
Actoplus Met is a brand name for a medicine that contains two active ingredients: pioglitazone and metformin.
Supported by provided label metadata: pioglitazone hydrochloride + metformin hydrochloride; dosage form oral tablet 15 mg/850 mg.
Actoplus Met contains a fixed combination of pioglitazone and metformin.
Supported by provided label metadata indicating fixed-dose strength (15 mg/850 mg).
Actoplus Met is used to treat type 2 diabetes.
Consistent with provided excerpts referring to antidiabetic medications and ACTOPLUS MET dosing/monitoring in the context of patients treated with antidiabetics (explicit indication text not provided in excerpts).
Actoplus Met is intended for adults with type 2 diabetes whose blood sugar is not controlled adequately with diet/exercise and/or other diabetes medicines.
General indication described; however the provided excerpts do not contain the full indication wording. Assessed as broadly consistent but not directly verifiable from provided CHF/lactic acidosis excerpts.
Pioglitazone can cause dose-related fluid retention and may lead to or exacerbate congestive heart failure; observe patients for signs and symptoms of CHF.
Provided excerpt 5.1 CHF warning and monitoring language.
Heart failure risk and fluid retention are key precautions with Actoplus Met because pioglitazone can worsen fluid retention in susceptible people.
Supported by 5.1 and 2.4 recommendations for monitoring fluid retention/CHF.
Kidney function is a key precaution with Actoplus Met because metformin dosing/safety depends on it.
Supported by excerpt 8.6 Renal Impairment indicating risk of accumulation and lactic acidosis increases with renal impairment and contraindication in eGFR <30.
When switching to or from Actoplus Met, dose changes may require calculating equivalent total daily doses of the individual components.
Plausible in context of fixed-dose strengths, but not explicitly supported by provided excerpts.
After initiation or with dosage increase, monitor patients carefully for adverse reactions related to fluid retention.
Supported by excerpt 2.4 monitoring language.
Unsupported Statements
Metformin lowers blood glucose by improving how the body uses insulin.
Mechanism statement not supported by provided label excerpts.
Metformin lowers blood glucose by reducing glucose production.
Mechanism statement not supported by provided label excerpts.
Pioglitazone improves insulin sensitivity in the body’s tissues.
Mechanism statement not supported by provided label excerpts.
Actoplus Met is especially used when one medicine alone does not work well enough.
Not supported by provided excerpts.
Dosing of Actoplus Met is individualized by clinicians.
Not supported by provided excerpts.
Dosing of Actoplus Met may be adjusted based on blood glucose results.
Not supported by provided excerpts.
Dosing of Actoplus Met may be adjusted based on how well the person tolerates the medicines.
Not supported by provided excerpts.
Common side effects can include GI symptoms such as nausea and stomach upset.
The provided excerpts do not state frequency or typical adverse reactions such as nausea/stomach upset.
GI symptoms occur more often from metformin.
Not supported by provided excerpts.
Weight gain or fluid retention occur more often with pioglitazone.
Not supported by provided excerpts in terms of relative frequency (the excerpts discuss monitoring and occurrence generally).
Liver health and other general safety monitoring are important with pioglitazone-containing therapy.
Hepatic impairment caution is mentioned in excerpt 8.7, but the claim about pioglitazone-containing therapy and broad 'liver health and other general safety monitoring' is not directly supported by the provided excerpts.
Actoplus Met can be taken with other diabetes medicines.
The provided excerpts mention use 'in combination with other antidiabetic medications' in the context of CHF risk, but do not support an explicit general counseling statement about concomitant diabetes medicines.
The exact combination of Actoplus Met with other diabetes medicines depends on the regimen and risks.
Not supported by provided excerpts.
Hypoglycemia risk varies by the other diabetes drugs.
Not supported by provided excerpts.
A prescriber should confirm compatibility with a patient’s current diabetes medications.
Not supported by provided excerpts.
Diabetes treatment choices in pregnancy and during breastfeeding often change.
Not supported by provided excerpts (no pregnancy/breastfeeding label text included).
A clinician should be asked whether Actoplus Met is appropriate during pregnancy, when trying to conceive, or during breastfeeding.
Not supported by provided excerpts.
When switching to or from Actoplus Met, dose changes may require calculating equivalent total daily doses of the individual components.
Not supported by provided excerpts.
Contradictions
Low
AI Statement
Common side effects can include GI symptoms such as nausea and stomach upset.
Label Reference
No direct contradiction available in provided excerpts, but considered unsupported rather than contradictory.
Important Omissions
Contraindication: ACTOPLUS MET is contraindicated in patients with established NYHA Class III or IV heart failure at the time of initiation.
Importance:
High
Lactic acidosis management/urgency: if suspected, discontinue immediately and institute supportive measures in a hospital; prompt hemodialysis recommended.
Importance:
High
Risk factors/monitoring for lactic acidosis: patient counseling to discontinue and promptly notify for unexplained hyperventilation, myalgia, GI symptoms, malaise, unusual somnolence, etc., and conditions predisposing to development.
Importance:
High
Specific renal/contrast guidance: discontinue at time of or prior to iodinated contrast imaging procedures in patients with eGFR 30–60 and also in patients with history of liver disease, alcoholism, or heart failure.
Importance:
Moderate
Use in hepatic impairment: ACTOPLUS MET is not recommended in patients with hepatic impairment.
Importance:
Moderate
Drug interaction specifics: carbonic anhydrase inhibitors (e.g., topiramate) and drugs that reduce metformin clearance may increase lactic acidosis risk; consider more frequent monitoring.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response highlights CHF/fluid retention and renal precautions, but omits key contraindication (NYHA III/IV) and critical lactic acidosis instructions (immediate discontinuation, hospital supportive care, prompt hemodialysis) that are explicitly present in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Material omissions of contraindication (NYHA Class III/IV) and lactic acidosis management/counseling details; multiple safety/side-effect/mechanism assertions are unsupported by provided excerpts.
Suggested Improvement
Add explicit contraindication for NYHA Class III/IV at initiation, include lactic acidosis warnings with immediate discontinuation and hospital management/hemodialysis, and restrict claims about mechanisms, GI frequency attribution, pregnancy/breastfeeding, and general combination therapy unless supported by the provided label text.